T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct

Cited by (195)

Items 101–195 of 195

1. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses
   Slava Stamova, Anja Feldmann, Marc Cartellieri, Claudia Arndt, Stefanie Koristka, Falko Apel, Rebekka Wehner, Marc Schmitz, Martin Bornhäuser, Malte v. Bonin et al. · 2012 · Analytical Biochemistry
2. A New Recombinant Single Chain Trispecific Antibody Recruits T Lymphocytes to Kill CEA (Carcinoma Embryonic Antigen) Positive Tumor Cells In Vitro Efficiently
   X.-B. Wang · 2004 · The Journal of Biochemistry
3. Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B‐cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia
   Sarah Elitzur, Nira Arad‐Cohen, Shlomit Barzilai‐Birenboim, Miriam Ben‐Harush, Bella Bielorai, Ronit Elhasid, Tamar Feuerstein, Gil Gilad, Alexander Gural, Mira Kharit et al. · 2019 · Pediatric Blood & Cancer
4. Blinatumomab-induced T cell activation at single cell transcriptome resolution
   Yi Huo, Zhen Sheng, Daniel Lu, Daniel Christian Ellwanger, Chi-Ming Li, Oliver R. Homann, Songli Wang, Hong Mei Yin, Ruibao Ren · 2021 · BMC Genomics
5. The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
   Li Peng, Michael D. Oberst, Jiaqi Huang, Philip Z. Brohawn, Chris Morehouse, Kristen J. Lekstrom, Patrick A. Baeuerle, Herren Wu, Yihong Yao, Steven R. Coats et al. · 2012 · PLoS ONE
6. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells
   Michael Schwemmlein, Julia Stieglmaier, Christian Kellner, Matthias Peipp, Domenica Saul, Fuat S. Oduncu, Bertold Emmerich, Bernhard Stockmeyer, Peter Lang, Jörn Dirk Beck et al. · 2007 · Leukemia
7. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia
   Stefan Klaus Barta, Yiyu Zou, John D. Schindler, Niraj Konchady Shenoy, Tushar Damodar Bhagat, Ulrich G. Steidl, Amit Verma · 2012 · Leukemia & lymphoma/Leukemia and lymphoma
8. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody‐based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells
   Claudia Arndt, Anja Feldmann, Katrin Töpfer, Stefanie Koristka, Marc Cartellieri, Achim Temme, Armin Ehninger, Gerhard Ehninger, Michael Philipp Bachmann · 2014 · The Prostate
9. Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
   Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien‐Hsing Chang, David M. Goldenberg · 2014 · Molecular Cancer Therapeutics
10. A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin
    Alessandra Villa, Valeria Lovato, Emil Bujak, Sarah Wulhfard, Nadine Pasche, Dario Neri · 2011 · mAbs
11. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager
    Ningqiang Gong, Xuexiang Han, Lulu Xue, Margaret M. Billingsley, Xisha Huang, Rakan D. El-Mayta, Jingya Qin, Neil C. Sheppard, Carl H. June, Michael J. Mitchell · 2024 · Nature Biomedical Engineering
12. Supraagonistic, bispecific single‐chain antibody purified from the serum of cloned, transgenic cows induces T‐cell‐mediated killing of glioblastoma cells <i>in vitro</i> and <i>in vivo</i>
    Grosse‐Hovest, Ludger, Wick, Wolfgang, Minoia, Rosa, Weller, Michael, Rammensee, Hans‐Georg, Brem, Gottfried, Jung, Gundram · 2005 · International Journal of Cancer
13. Blinatumomab for the Treatment of Philadelphia Chromosome–Negative, Precursor B-cell Acute Lymphoblastic Leukemia
    Ofir Wolach, Richard Maury Stone · 2015 · Clinical Cancer Research
14. Antitumor Activities of PSMA×CD3 Diabodies by Redirected T-cell Lysis of Prostate Cancer Cells
    Volker Baum, Patrick Bühler, Dorothee Gierschner, Dieter Herchenbach, Gina J. Fiala, Wolfgang W A Schamel, Philipp Wolf, Ursula Elsässer‐Beile · 2012 · Immunotherapy
15. Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape
    Daniel H. Park, Kevin Liaw, Pratik Sanjivkumar Bhojnagarwala, Xizhou Zhu, Jihae Choi, Ali Ali, Devivasha Bordoloi, Ebony Nicole Gary, Ryan P. O’Connell, Abhijeet J. Kulkarni et al. · 2023 · Molecular Therapy — Oncolytics
16. Immunotherapy in Renal Cell Carcinoma
    Annkristin Heine, Tobias A.W. Holderried, Peter Brossart · 2008 · Immunotherapy
17. Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
    Irene Michalk, Anja Feldmann, Stefanie Koristka, Claudia Arndt, Marc Cartellieri, Armin Ehninger, Gerhard Ehninger, Michael Philipp Bachmann · 2014 · PLoS ONE
18. Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model
    Jiwon Yang, Jing Jiao, Kyle Draheim, Guoxiang Yang, Hongyuan Yang, Li‐Chin Yao, Leonard D. Shultz, Dale L. Greiner, Deepa Rajagopal, Sandrine Vessillier et al. · 2023 · The FASEB Journal
19. Immunotherapy of B‐cell non‐Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model
    Hossein Panjideh, Gerd Müller, Mathias Koch, Frank Wilde, Susanne Scheu, Gerhard Moldenhauer, Martin Lipp · 2014 · International Journal of Cancer
20. Advances in new targets for immunotherapy of small cell lung cancer
    Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu · 2023 · Thoracic Cancer
21. Strategies to Overcome Hurdles in Cancer Immunotherapy
    Jihyun H. Kim, Byung Joon Lee, Sehoon Moon, Hojeong Lee, Ju‐Yong Lee, Byung‐Soo Kim, Keehoon Jung, Hyungseok Seo, Yeonseok Chung · 2024 · Biomaterials Research
22. Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1
    Julie Katrin Fierle, Matteo Brioschi, Mariastella de Tiani, Laureline Wetterwald, Vassilios Atsaves, Johan Abram-Saliba, Tatiana V. Petrova, George Coukos, Steven Mark Dunn · 2021 · Cell Reports Medicine
23. Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody
    Annika Wulf-Goldenberg, Klaus Eckert, Iduna Fichtner · 2010 · Cytotherapy
24. Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies
    Ho‐Young Lee, Edward Contreras, Ames C. Register, Qiang Wu, Kathleen Abadie, Khristofer Garcia, Pin Yee Wong, Guoying Jiang · 2019 · Scientific Reports
25. Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing
    Tyler F. Hill, Parnal Narvekar, Gregory D. Asher, Jasmine Edelstein, Nathan D. Camp, Annaiz Grimm, Kerri R. Thomas, Michael D Leiken, Katherine Molloy, Peter J. Cook et al. · 2024 · Molecular Therapy
26. Rationale and development of multispecific antibody drugs
    Jijie Gu, Tariq Ghayur · 2010 · Expert Review of Clinical Pharmacology
27. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
    Joshua F. Meckler, Daniel J. Levis, D. Vang, J. Tuscano · 2023 · Cancer Immunology and Immunotherapy
28. Bispecific antibodies for the treatment of neuroblastoma
    Madelyn M. Espinosa-Cotton, Nai‐Kong V. Cheung · 2022 · Pharmacology & Therapeutics
29. Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms
    Paola Circosta, Angela Rita Elia, Indira Landra, Rodolfo Machiorlatti, Maria Todaro, Sabrina Aliberti, Davide Brusa, Silvia Deaglio, Sabina Chiaretti, Riccardo Bruna et al. · 2017 · OncoImmunology
30. Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli
    Juanni Liu, Ming Yang, Jinhong Wang, Yuanfu Xu, Yan Wang, Xiaofeng Shao, Chunzheng Yang, Yingdai Gao, Dongsheng Xiong · 2009 · Cancer Immunology Immunotherapy
31. Bispecific antibodies in acute lymphoblastic leukemia therapy
    Guranda Chitadze, Anna Laqua, Marcus Lettau, Claudia Dorothea Baldus, Monika Brüggemann · 2020 · Expert Review of Hematology
32. Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules
    Ho‐Young Lee, Ames C. Register, Jeongsup Shim, Edward Contreras, Qiang Wu, Guoying Jiang · 2019 · mAbs
33. Recent Advancements in Cell-Based Therapies in Melanoma
    George Nassief, Angela Anaeme, Karen Moussa, Abdallah Mansour, George Ansstas · 2024 · International Journal of Molecular Sciences
34. Update on developmental therapeutics for acute lymphoblastic leukemia
    Malcolm Anders Smith · 2009 · Current Hematologic Malignancy Reports
35. Alternative Protein Scaffolds as Novel Biotherapeutics
    Michaela Gebauer, Arne Skerra · 2015 · AAPS advances in the pharmaceutical sciences series
36. Bispezifische Antikörper
    M. A. Ströhlein, M. M. Heiss · 2012 · Der Onkologe
37. Bispecific Antibodies
    Dafne Müller, Roland E. Kontermann · 2007 · Wiley eBooks
38. Immunotherapy for Meningiomas
    Hans‐Georg Wirsching, Michael Weller · 2023 · Advances in experimental medicine and biology
39. Predictive In Vivo Models for Oncology
    Diana Behrens, Jana Rolff, Jens Hoffmann · 2015 · Handbook of experimental pharmacology
40. Design and expression of a bispecific antibody against dengue and chikungunya virus in plants
    Adrian Esqueda, Collin Jugler, Qiang Chen · 2021 · Methods in enzymology on CD-ROM/Methods in enzymology
41. Update on Novel Monoclonal Antibodies anD Immunoconjugates for the Treatment of Lymphoproliferative Disorders
    Lyudmyla Derby, Myron Stefan Czuczman · 2011 · Future Oncology
42. SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
    Ryan Joseph Sullivan, Anthony Richard Cillo, Robert Louis Ferris, Russell William Jenkins, Harriet M. Kluger, Marleen Kok, Evan J. Lipson, Luca Paruzzo, William L. Redmond, Marco Ruella et al. · 2025 · Journal for ImmunoTherapy of Cancer
43. Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
    Edo Kapetanovic, Cédric R. Weber, Marine Bruand, Daniel Pöschl, Jakub Kucharczyk, Elisabeth Hirth, Claudius L. Dietsche, Riyaz Ahmed Khan, Bastian Wagner, Olivier Belli et al. · 2024 · Nature Biomedical Engineering
44. Compact Seahorse‐Shaped T Cell–Activating Antibody for Cancer Therapy
    Hiroto Fujii, Yoshikazu Tanaka, Hikaru Nakazawa, Aruto Sugiyama, Noriyoshi Manabe, Akira Shinoda, Nobutaka Shimizu, Takamitsu Hattori, Katsuhiro Hosokawa, Takuma Sujino et al. · 2018 · Advanced Therapeutics
45. Bispecific Antibodies: Developments and Current Perspectives
    Roland E. Kontermann · 2011 · Springer eBooks
46. Novel monoclonal antibody-based therapies for leukemia
    Osmond J. D’Cruz, Fatih Mehmet Uckun · 2013
47. Optimization of a Novel 2 + 2 BCMA × CD3 Bispecific Antibody for Minimized Cytokine Release and Potent Efficacy
    Danqing Wu, Lini Huang, Naren Gaowa, Rui Zhang, Shiyong Gong, Xuan Wu, Chengbin Wu · 2025 · Molecular Cancer Therapeutics
48. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis
    Bryan D. Choi, Patrick C. Gedeon, Chien‐Tsun Kuan, Luis A Sanchez-Perez, Gary E. Archer, Darell D. Bigner, John Howard Sampson · 2013 · Journal of Immunological Methods
49. Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds
    Vala Kafil, Amir Ata Saei, Mohammad Reza Tohidkia, Jaleh Barar, Yadollah Omidi · 2020 · Journal of drug targeting
50. Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V
    Changchang Lu, Lu Zou, Qiaoli Wang, Mengna Sun, Tianyu Shi, Xu Shuang, Fanyan Meng, Juan Du · 2024 · Biomolecules and Biomedicine
51. A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes
    Marcel Zocher, Patrick A. Baeuerle · 2004 · Molecular Immunology
52. Effector Cell Recruitment by Bispecific Antibodies
    Christian Kellner, Matthias Peipp, Thomas Valerius · 2011 · Springer eBooks
53. CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager
    Andisheh Bagheri, Patricia Culp, Robert B. DuBridge, Tseng-hui Timothy Chen · 2022 · Biochemistry and Biophysics Reports
54. Construction and functional analysis of an anti-human cervical carcinoma/anti-human CD3 single-chain bispecific antibody
    Hong Wu, Yao Li, LIN CHOU, Jinhua Yang, YUN-XIU ZHANG, X. Li, Boer Shan · 2016 · Molecular Medicine Reports
55. Immunotherapy of lymphoma: update and review of the literature
    Jesús G. Berdeja · 2003 · Current Opinion in Oncology
56. Rapid, site-specific labeling of “off-the-shelf” and native serum autoantibodies with T cell–redirecting domains
    Fabiana Zappala, Elizabeth M. Higbee-Dempsey, Bian Jang, Joann M. Miller, Lesan Yan, Nicholas G. Minutolo, Gabriela T. Rosado-González, Andrew Tsourkas, Burcin Altun · 2022 · Science Advances
57. Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
    Daniel R. Reed, Lawrence G. Lum · 2024 · Expert Opinion on Biological Therapy
58. Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives
    Shuangsi Liao, Xiaoling Li, You Lü, Kui Luo · 2025 · Small Methods
59. T-cell engaging bispecific antibody therapy
    Patty A. Culp, Jeremiah D. Degenhardt, Danielle E. Dettling, Chad May · 2021 · Elsevier eBooks
60. Bispecific T Cell Engager for Cancer Therapy
    Patrick A. Baeuerle, Gerhard Zugmaier, Dominik Rüttinger · 2011 · Springer eBooks
61. Bispecific Antibodies and Immune Therapy Targeting
    Sergej M. Kiprijanov · 2011
62. LegoBody: facile generation of bispecific and multi-specific antibodies
    Shanshan Lang, Su Yang, Scott M. Bidlingmaier, Nam-Kyung Lee, Bin Liu · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
63. T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases
    A. S. Vdovin, Н. А. Быкова, Grigory Aleksandrovich Efimov · 2017 · Molecular Biology
64. SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia
    Ashley E. Pinchinat, Sumit Gupta, Stacy Cooper, Rachel E. Rau · 2022 · Clinical Lymphoma Myeloma & Leukemia
65. Recombinant Bispecific Antibodies for Cancer Therapy
    Dafne Müller, Roland E. Kontermann · 2011 · Cell engineering
66. Early De-risking Strategy for Novel Biotherapeutics
    Padma Kumar Narayanan, Rafael A. Ponce, Beth Hinkle · 2013 · Elsevier eBooks
67. Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia
    Christiane I.-U. Chen · 2017 · Springer eBooks
68. Les anticorps bispécifiques : une vieille histoire pleine d’avenir… avec les CAR-T !
    Clémence Riffard, Jean‐Luc Teillaud · 2021 · Bulletin du Cancer
69. Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy
    Lawrence G. Lum, Archana B. Thakur · 2011 · Springer eBooks
70. Development of T‐Cell‐Engaging Bispecific Antibody Blinatumomab (Blincyto®) for Treatment of B‐Cell Malignancies
    Patrick A. Baeuerle · 2018
71. Multiple antibody and multi-specificity approaches
    2012 · Elsevier eBooks
72. Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
    Agnes Banaszek · 2013 · Online Publication Service of Würzburg University (Würzburg University)
73. References
    2012 · Elsevier eBooks
74. T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells
    Matthias Obenaus, Clara L. Poupault, Christopher S. McGinnis, Céline Jasmin Prange, Hua Jiang, Leon Su, Xiaojing Tina Chen, Zhuang Miao, Joseph J. Muldoon, Winnie Yao et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
75. Desarrollo de nuevas estrategias de inmunoterapia antitumoral basadas en la secreción in vivo de anticuerpos biespecíficos
    Marta Compte · 2013 · Biblos-e Archivo (Universidad Autónoma de Madrid)
76. Improvement of pharmacokinetics of small recombinant bispecific antibody molecules
    Christoph Roland Stork · 2009 · OPUS Publication Server of the University of Stuttgart (University of Stuttgart)
77. Promises and Challenges with Immunomodulatory Biologics
    Rafael A. Ponce · 2014 · Wiley eBooks
78. Bifunctional Antibodies: Preclinical and Clinical Applications
    Casey W. Shuptrine, Louis M. Weiner · 2013 · Springer eBooks
79. WITHDRAWN: Tetravalent Bispecific Single-Chain Fv Antibodies for Lysis of Leukemia Cells by Autologous T Cells
    Fabrice Le Gall, Uwe Reusch, Anastasia Bakulina, Sergej M. Kiprijanov · 2012 · Journal of Molecular Biology
80. Development of T cell based therapeutic strategies for childhood cancer neuroblastoma
    Aysha Patel · 2017 · UCL Discovery (University College London)
81. Genetically Engineered T Cell Therapies and Immune System Engagers for Graft-Versus-Host Disease and Graft Versus Leukemia
    Terry J. Fry, Elad Jacoby · 2019 · Elsevier eBooks
82. Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia
    Sumit Gupta, Stacy Cooper, Rachel E. Rau · 2021 · Clinical Lymphoma Myeloma & Leukemia
83. Data from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
    Scott A. Hammond, Ralf Lutterbuese, Shannon R. Roff, Petra Lutterbuese, Bernd Schlereth, Elizabeth Bruckheimer, Michael S. Kinch, Steve Coats, Patrick A. Baeuerle, Peter Kufer et al. · 2023
84. Data from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
    Scott A. Hammond, Ralf Lutterbuese, Shannon R. Roff, Petra Lutterbuese, Bernd Schlereth, Elizabeth Bruckheimer, Michael S. Kinch, Steve Coats, Patrick A. Baeuerle, Peter Kufer et al. · 2023
85. Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
    Madelyn M. Espinosa-Cotton, Hong-Fen Guo, Nai‐Kong V. Cheung · 2023 · Journal of Visualized Experiments
86. An immunocompetent model to uncover the secrets of bispecifics
    Joseph E. Maakaron · 2024 · Blood Advances
87. Additional file 2 of Blinatumomab-induced T cell activation at single cell transcriptome resolution
    Yi Huo, Zhen Sheng, Daniel Lu, Daniel Christian Ellwanger, Chi-Ming Li, Oliver R. Homann, Songli Wang, Hong Yin, Ruibao Ren · 2021 · Figshare
88. Additional file 5 of Blinatumomab-induced T cell activation at single cell transcriptome resolution
    Yi Huo, Zhen Sheng, Daniel Lu, Daniel Christian Ellwanger, Chi-Ming Li, Oliver R. Homann, Songli Wang, Hong Mei Yin, Ruibao Ren · 2021 · Figshare
89. Additional file 4 of Blinatumomab-induced T cell activation at single cell transcriptome resolution
    Yi Huo, Zhen Sheng, Daniel Lu, Daniel Christian Ellwanger, Chi-Ming Li, Oliver R. Homann, Songli Wang, Hong Yin, Ruibao Ren · 2021 · Figshare
90. Additional file 6 of Blinatumomab-induced T cell activation at single cell transcriptome resolution
    Yi Huo, Zhen Sheng, Daniel Lu, Daniel Christian Ellwanger, Chi-Ming Li, Oliver R. Homann, Songli Wang, Hong Mei Yin, Ruibao Ren · 2021 · Figshare
91. Early de-risking strategy for biotherapeutics
    Padma Kumar Narayanan, Anna Dahlman, Ping Peng · 2024 · Elsevier eBooks
92. Antibody-Redirected T-Cell Immunotherapy for Brain Tumors
    Bryan D. Choi · 2014 · DukeSpace (Duke University)
93. Additional file 3 of Blinatumomab-induced T cell activation at single cell transcriptome resolution
    Huo, Yi, Sheng, Zhen, Daniel Lu, Daniel Christian Ellwanger, Li, Chi-Ming, Oliver R. Homann, Wang, Songli, Yin, Hong, Ren, Ruibao · 2021 · Figshare
94. Additional file 1 of Blinatumomab-induced T cell activation at single cell transcriptome resolution
    Yi Huo, Sheng, Zhen, Daniel Lu, Daniel Christian Ellwanger, Li, Chi-Ming, Oliver R. Homann, Wang, Songli, Yin, Hong, Ren, Ruibao · 2021 · Figshare
95. Bench-to-Bedside Perspectives on the Development of Soluble TCR-Based Protein Biologics: Current Landscape, Control Strategy and Future Direction
    Jingyi Zhang, Hongxin An, 于传飞, Weiyu Li, Meng Li, Lan Wang · 2026 · International Journal of Molecular Sciences